Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases

Uka, Kiminori; Aikata, Hiroshi; Takaki, Shintaro; Kawaoka, Tomokazu; Saneto, Hiromi; Miki, Daiki; Takahashi, Shoichi; Toyota, Naoyuki; Ito, Katsuhide; Chayama, Kazuaki

doi:10.3748/wjg.14.2602

Cited by 4 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response rates obtained in the present study were similar to those obtained in the report by Uka et al [21] and lower than those obtained in the other two reports. This discrepancy may be explained by the different criteria used to evaluate antitumor efficacy, as Uka et al [21] suggested in their discussion. Obi et al [13] and Ota et al [18] used the Eastern Clinical Oncology Group criteria, whereas Uka et al [21] and the present study used the Response Evaluation Criteria in Solid Tumors.…”

Section: Discussionsupporting

confidence: 64%

“…This discrepancy may be explained by the different criteria used to evaluate antitumor efficacy, as Uka et al [21] suggested in their discussion. Obi et al [13] and Ota et al [18] used the Eastern Clinical Oncology Group criteria, whereas Uka et al [21] and the present study used the Response Evaluation Criteria in Solid Tumors.…”

Section: Discussionmentioning

confidence: 96%

“…We previously reported a response rate of 45% in 34 patients who underwent multidrug HAIC using FU and CDDP in combination with IFN treatment [11]. Uka et al [21] used IFN in combination with HAIC using FU in 55 patients who had a tumor embolus of the portal vein and reported a response rate of 29%. The response rates obtained in the present study were similar to those obtained in the report by Uka et al [21] and lower than those obtained in the other two reports.…”

Section: Discussionmentioning

confidence: 99%

“…Obi et al [13] also reported that positivity for HCV-Ab was a predictor of a CR to IFN combined with HAIC using FU. Uka et al [21] reported that positivity for HCV-Ab was a factor associated with the early antitumor effect, progression-free time and overall survival after IFN combined with HAIC. Thus, positivity for HCV-Ab was determined to be a factor that improved prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…Uka et al [21] used IFN in combination with HAIC using FU in 55 patients who had a tumor embolus of the portal vein and reported a response rate of 29%. The response rates obtained in the present study were similar to those obtained in the report by Uka et al [21] and lower than those obtained in the other two reports. This discrepancy may be explained by the different criteria used to evaluate antitumor efficacy, as Uka et al [21] suggested in their discussion.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma

et al. 2011

View full text Add to dashboard Cite

Objective: This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC). Methods: A total of 114 patients with measurable advanced HCC were enrolled and randomized into 2 groups. FU (300 mg/m², days 1–5, days 8–12) with or without CDDP (20 mg/m², days 1 and 8) was administered via the hepatic artery. IFNα-2b was administered 3 times per week for 4 weeks. Results: The response rates were 45.6% for the IFN/FU + CDDP group and 24.6% for the IFN/FU group. The response rate was significantly higher in the IFN/FU + CDDP group (p = 0.030). The median overall survival period was 17.6 months in the IFN/FU + CDDP group versus 10.5 months in the IFN/FU group (p = 0.522). The median progression-free survival period was 6.5 months in the IFN/FU + CDDP group versus 3.3 months in the IFN/FU group (p = 0.0048). Hematological toxicity was common, but no toxicity-related deaths were observed. Conclusion: These results show the clinical efficacy of adding CDDP to the hepatic arterial infusion of FU in combined chemotherapy regimens with IFN.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma

et al. 2011

View full text Add to dashboard Cite

show abstract

Assessment of Health Related Quality of Life in Chronic Liver Disease Patients Using the Japanese Versions of CLDQ and SF-36

Mahmood¹,

Kida²,

Izumi³

et al. 2008

TOGASJ

View full text Add to dashboard Cite

Liver disease affects health-related quality of life. The CLDQ is a liver disease specific questionnaire. This study attempted to translate the original CLDQ into Japanese and compare it with SF-36 in chronic liver disease patients, mainly chronic hepatitis C. The Japanese versions of CLDQ and SF-36 were administered to 120 CHC; 45 CHB; 29 NAFLD; 21 HCC post treatment and 50 healthy controls, between February and March, 2008. CLDQ scores of CHC patients and controls were unaffected by sex and age. SF-36 scores of female CHC patients were significantly lower (P = 0.0081) compared to male in the domain of physical function. CHC patients over 70 years had significantly lower SF-36 scores in multiple domains compared to CHC patients below 70. CLDQ scores of CHC patients were lower than controls in all 6 domains. CHB & NAFLD patients had significantly low scores in 3 domains, compared to controls. CHC patients scored significantly lower than CHB & NAFLD patients in 2 domains. Significant differences in SF-36 scores between controls, CHC, CHB and NAFLD patients were not observed. CLDQ scores of treatment naïve CHC patients, having ALT levels (40 or 40) IU/l; liver cirrhosis patients (child Pugh A) and HCC patients post treatment, revealed that HCC and cirrhosis patients had similar CLDQ scores and significantly lower scores compared to CHC patients with ALT 40 IU/l in 5 out of 6 domains. CHC patients with ALT 40 IU/l had significantly lower CLDQ scores than CHC patients with ALT 40 IU/l in 3 domains. Similar differences was not observed using the SF-36. CLDQ gave a better understanding of HRQL in patients with different forms of chronic liver disease and also disease progression. Age and sex did not affect CLDQ scores. CLDQ appears to be a more convenient tool to study the HRQL in chronic liver disease patients.

show abstract

Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

Miyahara

Nouso

Yamamoto

2014

WJG

View full text Add to dashboard Cite

The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC). After development of sorafenib and its introduction as a therapeutic agent used in the clinic, several critical questions have been raised. Clinical parameters and biomarkers predicting sorafenib efficacy are the most important issues that need to be elucidated. Although it is difficult to know the responders in advance using conventional characteristics of patients, there are specific serum cytokines and/or gene amplification in tumor tissues that have been reported to predict efficacy of sorafenib. Risk and benefits of continuation of sorafenib beyond radiological progression is another issue to consider because no other standard therapy for advanced HCC as yet exists. In addition, effectiveness of the expanded application of sorafenib is still controversial, although a few studies have shed some light on combinational treatment with sorafenib for intermediate-stage HCC. Recently, over 50 relevant drugs have been developed and are currently under investigation. The efficacy of some of these drugs has been extensively examined, but none have demonstrated any superiority over sorafenib, so far. However, there are several drugs that have shown efficacy for treatment after sorafenib failure, and these are proceeding to further studies. To address these issues and questions, we have done extensive literature review and summarize the most current status of therapeutic application of sorafenib.

show abstract

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases

Cited by 4 publications

References 25 publications

Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma

Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma

Assessment of Health Related Quality of Life in Chronic Liver Disease Patients Using the Japanese Versions of CLDQ and SF-36

Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

Contact Info

Product

Resources

About